Clik here to view.
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the...
View ArticleClik here to view.
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual...
View ArticleClik here to view.
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS®...
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of...
View ArticleClik here to view.
Maruho和Solasia签署SP-04(PledOx®)代理许可及资本联盟协议
日本东京 (美国商业资讯)–苏爱康制药有限公司（东京证券交易所代码：4597，总部：日本东京，总裁兼首席执行官：荒井好裕，以下简称“苏爱康”）和Maruho有限责任公司（总部：日本大阪，总裁兼首席执行官：Koichi Takagi,...
View ArticleClik here to view.
ソレイジア・ファーマ: 開発品SP-04(効能・効果：がん化学療法に伴う末梢神経障害) 日本における独占的販売ライセンス契約締結および資本提携のお知らせ
東京 （ビジネスワイヤ） — マルホ株式会社（以下「マルホ」）とソレイジア・ファーマ株式会社（以下「ソレイジア」）は、ソレイジアが開発している開発品SP-04...
View ArticleClik here to view.
Solasia Announces License and Capital Alliance for SP-04 (PledOx®) with Maruho
TOKYO Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) announced today that it has entered into an exclusive license agreement...
View ArticleClik here to view.
武田薬品がアミロイドーシス患者でニンラーロを検討する第3相TOURMALINE-AL1試験の結果を発表へ
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
武田将呈报评估NINLARO用于淀粉样变患者的3期TOURMALINE-AL1试验结果
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE:4502/NYSE:TAK)今天宣布，TOURMALINE-AL1试验结果将于2019年12月7日周六在佛罗里达州奥兰多召开的美国血液学会(ASH)第61届年会上口述呈报。TOURMALINE-AL1是3期随机临床试验，评估NINLAROTM...
View ArticleClik here to view.
武田在ASH 2019上呈报的研究重点介绍真实世界证据和在研基因治疗药物，展现其促进罕见出血障碍治疗的长期承诺
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502/NYSE:TAK)（“武田”）今天在美国血液学会(ASH)第61届年会上呈报9篇血液学壁报，介绍了该公司通过整合真实世界数据和开发创新腺相关病毒(AAV)基因治疗药物促进罕见出血障碍治疗的承诺。 了解真实世界证据，以促进出血障碍患者为中心的创新...
View ArticleClik here to view.
DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today presented positive detailed data from the global pivotal phase 2...
View ArticleClik here to view.
Fully-human BCMA CAR-T Clinical Results for the Treatment of...
NANJING, China IASO Biotherapeutics (IASO Bio), a clinical-stage biotechnology company advancing the development of innovative therapies for cancer, had the latest clinical data presented on their...
View ArticleClik here to view.
PCI Pharma Services宣布巨额投资，扩建位于英国Tredegar厂区的开发和制造能力
费城 (美国商业资讯)–领先的制药和生物制药全球外包解决方案提供商PCI Pharma Services (PCI)今天宣布，已开始扩建其位于英国威尔士的Tredegar设施，以提升其高效价药物制造和开发能力，包括临床和商业两方面的供货。...
View ArticleClik here to view.
Seattle Genetics和武田在ASH 2019年会上发布 ADCETRIS® (Brentuximab Vedotin)...
华盛顿州博瑟尔和马萨诸塞州剑桥和日本大阪 (美国商业资讯)– Seattle Genetics, Inc. (Nasdaq:SGEN)和武田药品工业株式会社(TSE:4502/NYSE:TAK)今天发布了ECHELON-1和ECHELON-2 ADCETRIS® (brentuximab...
View ArticleClik here to view.
武田薬品、実臨床下でのエビデンスと遺伝子療法治験薬に光を当てる研究の発表をASH 2019で行い、希少出血性疾患の治療を前進させる長期的なコミットメントを示す
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
Osaka University and Fuzionaire Radioisotope Technologies K.K. to Jointly...
TOKYO & OSAKA, Japan Fuzionaire Radioisotope Technologies K.K. (“FRIT”), a Japanese affiliate of radiopharmaceutical company Fuzionaire Diagnostics, Inc. (“Fuzionaire Dx”), today announced a...
View ArticleClik here to view.
21St Century Oncology to Join Australia’s GenesisCare in a Partnership to...
FORT MYERS, Fla. Cancer patients in communities across the U.S. are expected to benefit from increased access to high quality cancer care, with U.S. provider of radiation therapy and integrated...
View ArticleClik here to view.
PCIファーマ・サービシズが英国トレデガー施設の開発・製造能力を拡大するための大規模投資を発表
フィラデルフィア (ビジネスワイヤ) — 世界規模で製薬／バイオ製薬アウトソーシングサービスを提供する一流企業のPCIファーマ・サービシズ（PCI）は本日、臨床供給および商業供給の両面において高薬理活性医薬品の製造・開発能力を強化すべく、英国ウェールズにある当社のトレデガー施設の拡張を開始したと発表しました。...
View ArticleClik here to view.
Genetron Health Announces Strategic Collaboration with CStone
BEIJING Recently, Genetron Health has announced strategic collaboration with CStone Pharmaceuticals (“CStone”), providing companion diagnostic development services and clinical sample testing...
View ArticleClik here to view.
シアトル・ジェネティクスと武田薬品がアドセトリス（ブレンツキシマブ・ベドチン）の第3相臨床試験のECHELON-1およびECHELON-2の追加解析データ...
米ワシントン州ボセル & マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic...
NEW YORK & TOKYO Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food and Drug Administration...
View Article